GLP-1 and PCOS: What Research Says About Polycystic Ovary Syndrome Treatment

## How PCOS and GLP-1 Are Connected

[PCOS symptoms](/pcos-symptoms) affect an estimated 8 to 13 percent of women of reproductive age, making it one of the most common hormonal disorders worldwide.¹ The condition involves a cluster of problems — irregular periods, high androgen levels, and small cysts on the ovaries — but at its root, insulin resistance plays a central role.

Insulin resistance is documented in up to 75 percent of women with PCOS.² When cells do not respond well to insulin, the pancreas compensates by producing more of it. That excess insulin then travels to the ovaries, where it stimulates androgen (male hormone) production. Higher androgens suppress ovulation, disrupt menstrual cycles, and drive many of the outward [PCOS symptoms](/pcos-symptoms) women experience, such as acne, excess hair growth, and irregular periods.

This is where GLP-1 receptor agonists enter the picture. GLP-1 (glucagon-like peptide-1) is a natural gut hormone that helps regulate blood sugar by triggering insulin release in a glucose-dependent way. Medications that mimic this hormone — including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) — reduce appetite, slow gastric emptying, and improve insulin sensitivity. By addressing insulin resistance directly, GLP-1 drugs for PCOS may interrupt the insulin-androgen feedback cycle that drives so many of the condition's symptoms.³

## What Research Shows

The evidence base for GLP-1 medications in PCOS is growing, though researchers note it is still developing. A 2024 meta-analysis published in Scientific Reports reviewed randomized controlled trials and found that GLP-1 receptor agonists significantly reduced BMI, waist circumference, fasting insulin levels, and total testosterone among women with PCOS.⁴

One notable 2024 randomized controlled trial examined the combination of semaglutide and metformin in overweight and obese women with PCOS. Compared to metformin alone, the combination therapy significantly reduced body weight and inflammatory markers while also improving menstrual irregularities and increasing natural pregnancy rates.⁵

A real-world analysis by Epic Research found that patients with PCOS using GLP-1 medications experienced a median weight loss of 11.5 percent after one year — compared to just 1.9 percent in those using metformin alone. This degree of weight reduction is clinically meaningful for a condition where even modest weight loss can have outsized effects on hormonal balance and reproductive function.⁶

Research also suggests that semaglutide polycystic ovary treatment may improve menstrual regularity through two separate pathways: by correcting the hormonal suppression caused by excess estrogen from fat tissue, and by directly lowering elevated LH (luteinizing hormone) levels driven by hyperinsulinemia (too much insulin).³ These findings suggest the benefits go beyond simple weight loss.

It is worth noting that current studies are limited by small sample sizes and variability between trials. Researchers across multiple reviews call for larger, well-designed randomized controlled trials before definitive conclusions can be drawn.

## Weight Loss and PCOS Improvement

For many women with PCOS, body weight is a key driver of symptom severity. Excess body fat worsens insulin resistance, elevates androgens, and further disrupts ovulation. Research suggests that losing just 5 to 10 percent of body weight may be enough to restore more regular menstrual cycles in some women.⁷

GLP-1 medications are among the most effective pharmacological tools currently available for weight loss. In large trials like STEP 1, semaglutide produced average weight reductions of around 15 percent over 68 weeks — significantly more than lifestyle changes alone. For women with PCOS who struggle to lose weight through diet and exercise (often because of the metabolic effects of insulin resistance itself), this represents a meaningful advantage.

The connection between weight loss drugs, PCOS fertility, and reproductive outcomes is also significant. As adipose (fat) tissue decreases, estrogen production from fat cells falls, which can relieve the hormonal suppression of ovulation. Women who were not ovulating regularly may find that ovulatory cycles return as body weight normalizes. This phenomenon has been described clinically as part of what some are calling the "Ozempic babies" trend — unintended pregnancies in women who regained fertility after starting GLP-1 therapy.

## The PCOS-Liver-Sleep Apnea Connection

PCOS does not exist in isolation. Women with this condition face significantly elevated risks for other serious conditions, and GLP-1 medications may address several of them simultaneously.

Research published in Fertility and Sterility found that women with PCOS have a two to four times higher risk of non-alcoholic fatty liver disease (NAFLD) — also called metabolic dysfunction-associated steatotic liver disease (MASLD) — compared to weight-matched healthy controls.⁸ Insulin resistance and elevated androgens together drive fat accumulation in the liver, even in women who are not overweight.

PCOS is also associated with a substantially higher risk of obstructive [sleep apnea](/sleep-apnea-symptoms) (OSA), a condition where breathing repeatedly stops during sleep. OSA in turn worsens insulin resistance and metabolic health, creating a difficult cycle. GLP-1 receptor agonists have shown promise for both of these comorbidities (conditions that occur alongside the primary condition). Studies found that liraglutide reduced liver fat levels by 44 percent in people with fatty liver disease. A meta-analysis found that GLP-1 medications reduced the apnea-hypopnea index (a measure of sleep apnea severity) by approximately 9.5 events per hour.⁹ For women with PCOS managing multiple overlapping conditions, this multi-pathway benefit may be particularly valuable.

## Fertility Considerations

One of the most discussed aspects of GLP-1 therapy in the context of PCOS is its potential effect on GLP-1 ovulation and fertility. A meta-analysis of 11 randomized controlled trials involving 840 women with PCOS found that GLP-1 use was associated with a 72 percent increase in the rate of spontaneous pregnancy compared to control groups.¹⁰

However, the relationship between GLP-1 medications and fertility requires careful management. Current guidelines recommend stopping semaglutide at least two months before attempting to conceive, with some fertility specialists recommending three months or longer. This allows the medication to fully clear the body. Animal studies have shown potential adverse effects on fetal development, and GLP-1 medications have not been adequately studied in pregnant women, making them contraindicated during pregnancy.

There is also an important interaction with oral contraceptives to be aware of. Because GLP-1 medications slow how quickly the stomach empties food and medications into the intestine, oral birth control pills may be absorbed less efficiently. A study found that hormone levels from birth control pills dropped by approximately 20 percent after just one dose of tirzepatide, a related GLP-1-based medication. Women using oral contraceptives while on a GLP-1 drug may want to discuss backup contraception options with their prescriber — especially important given that restoring ovulation can happen unexpectedly.

## Current Limitations and Next Steps

GLP-1 receptor agonists are not currently FDA-approved specifically for the treatment of PCOS. Their use in this context is considered off-label, meaning prescribers may choose to use them based on emerging evidence and individual clinical judgment, but there is not yet formal regulatory endorsement for this indication.

The most common FDA-approved indications — type 2 diabetes, obesity, and cardiovascular risk reduction — do overlap with many PCOS presentations. A physician, endocrinologist, or reproductive specialist can evaluate whether a GLP-1 medication is appropriate given a patient's full clinical picture.

Researchers across multiple review papers emphasize that while the early data is promising, larger and more rigorous randomized controlled trials are still needed. Studies to date have often been short-term, enrolled small numbers of participants, or lacked consistency in outcome measures. Ongoing registered trials are examining semaglutide specifically in women with PCOS and obesity, which should provide cleaner data in the coming years.

If you have PCOS and are curious about GLP-1 medications, the best step is to discuss your specific symptoms, metabolic profile, and reproductive goals with your healthcare provider. An endocrinologist or OB-GYN specializing in reproductive endocrinology can help evaluate whether this approach fits your situation.

## When to See a Doctor

You may want to seek medical evaluation if you experience any of the following, which may suggest PCOS or a related metabolic condition:

- Irregular or absent menstrual periods

- Unexpected weight gain, particularly around the abdomen

- Signs of excess androgens such as acne, hair loss from the scalp, or increased facial or body hair

- Difficulty becoming pregnant after trying for 12 months (or 6 months if you are over 35)

- Persistent fatigue, excessive thirst, or frequent urination (which may indicate insulin resistance or diabetes)

- Loud snoring or waking frequently during sleep (which may suggest [sleep apnea](/sleep-apnea-symptoms))

If you are already managing PCOS and are interested in discussing GLP-1 medications, bring a list of your current medications, recent lab results, and your specific goals to your appointment. This helps your provider make an informed, personalized recommendation.

## Conclusion

GLP-1 receptor agonists represent a genuinely promising avenue for addressing PCOS and polycystic ovary syndrome across multiple biological pathways simultaneously. Early clinical evidence suggests benefits for insulin resistance, androgen levels, menstrual regularity, and even fertility. The medications may also help manage co-occurring conditions like fatty liver disease and sleep apnea that are more common in women with PCOS.

At the same time, this field is evolving rapidly. GLP-1 drugs are not yet specifically approved for PCOS, and the evidence base — while encouraging — still needs larger trials to solidify clinical recommendations. If you have PCOS and are considering whether GLP-1 therapy might be appropriate for you, work closely with a qualified healthcare provider who can assess your individual situation.

---

## References

1. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction. 2016;31(12):2841–2855. https://doi.org/10.1093/humrep/dew218

2. Murri M, et al. The Role of GLP-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences. 2022;23(8):4334. https://pmc.ncbi.nlm.nih.gov/articles/PMC9029608/

3. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. Journal of Clinical Endocrinology and Metabolism. 2020;105(8). https://pmc.ncbi.nlm.nih.gov/articles/PMC7457958/

4. Zhao H, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports. 2025. https://www.nature.com/articles/s41598-025-99622-4

5. Zhang Y, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12297736/

6. Epic Research. GLP-1s Lead to Greater Weight Loss and A1C Improvement Than Metformin in Patients with PCOS. 2024. https://www.epicresearch.org/articles/glp-1s-lead-to-greater-weight-loss-and-a1c-improvement-than-metformin-in-patients-with-pcos

7. Lim SS, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2019. https://pubmed.ncbi.nlm.nih.gov/39178623/

8. Vassilatou E, et al. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertility and Sterility. 2022;117(5):1099–1109. https://pubmed.ncbi.nlm.nih.gov/35512974/

9. Giovanella S, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/39626095/

10. Xinhai Y, et al. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. PMC. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10532286/

---

**Medical Disclaimer**: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. The information presented here should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health, please seek immediate medical attention.